managing relapsed all: the role of novel cellular therapies & importance of conditioning regimens
Published 7 months ago • 124 plays • Length 2:06Download video MP4
Download video MP3
Similar videos
-
0:57
novel therapeutic strategies in all
-
1:09
the changing role of allosct in dlbcl in the era of novel agents
-
2:18
treating patients with advanced-stage hl in the frontline and relapsed settings in 2024
-
3:10
novel aml treament approaches
-
1:13
selecting conditioning regimens for patients with myelofibrosis undergoing allosct
-
52:07
webinar - food allergen management
-
58:27
laboratory nonconformance (event) management
-
2:27
hyaluronidase for ha filler complications: dosage, timing & safety
-
4:18
significance of cell polarity in the ageing of hematopoietic stem cells
-
2:08
hematological response to frontline treatment in lr-mds is associated with better os
-
0:58
management strategies for acute and chronic gvhd following allosct
-
4:32
recent advances in the treatment of lr-mds: commands and imerge trial data
-
1:16
current therapeutic combinations and optimizing the sequencing of drugs in lr-mds
-
1:57
enhancing clinical care in lr-mds: managing symptomatic/transfusion-dependent anemia
-
1:05
the importance of using mrd to guide treatment decisions in all
-
1:52
phase i dose-escalation study of the bet inhibitor incb057643 in r/r myelofibrosis
-
2:47
using artificial intelligence to estimate overall mortality and non-relapse mortality after allosct
-
0:56
microbiota in hematologic malignancies
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond
-
3:37
progress in the categorization and treatment of lr-mds
-
2:29
the role of the multidisciplinary team in providing adequate diagnosis & treatment for bpdcn